

TEVA PHARMACEUTICAL INDUSTRIES LTD  
Form 8-K  
May 02, 2019

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported) May 2, 2019**

---

**TEVA PHARMACEUTICAL INDUSTRIES LIMITED  
(Exact name of registrant as specified in its charter)**

---

|                                     |                     |                       |
|-------------------------------------|---------------------|-----------------------|
| <b>Israel</b>                       | <b>001-16174</b>    | <b>Not Applicable</b> |
| <b>(State or Other Jurisdiction</b> | <b>(Commission</b>  | <b>(IRS Employer</b>  |
| <b>of Incorporation)</b>            | <b>File Number)</b> | <b>Identification</b> |
|                                     |                     | <b>No.)</b>           |

**5 Basel Street  
P.O. Box 3190  
Petach Tikva 4951033, Israel  
(Address of Principal Executive Offices, including Zip Code)**

**+972-3-914-8171  
(Registrant's Telephone Number, including Area Code)**

**Not Applicable  
(Former Name or Former Address, if Changed Since Last Report)**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Edgar Filing: TEVA PHARMACEUTICAL INDUSTRIES LTD - Form 8-K

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**ITEM 2.02 Results of Operations and Financial Condition**

On May 2, 2019, Teva Pharmaceutical Industries Ltd. issued a press release announcing its financial results for the period ended March 31, 2019. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and the information contained therein is incorporated herein by reference.

The information included in this Item 2.02 is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**ITEM 9.01 Financial Statements and Exhibits**

(d) Exhibits

**Exhibit**

| <b>No.</b>  | <b>Description of Document</b>                           |
|-------------|--|
| <u>99.1</u> | <u>Teva Reports First Quarter 2019 Financial Results</u> |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**TEVA PHARMACEUTICAL  
INDUSTRIES LTD.**

Date: May 2, 2019 By: /s/ Michael McClellan

Name: Michael McClellan

Title: Executive Vice President, Chief  
Financial Officer